iDNA Genomics Public (CYS:IDNA) ROE %: 0.00% (As of . 20)


CYS:IDNA iDNA Genomics Public Ltd CYS:IDNA
23 GF Score
Price €22.80
! 2 Warning Signs
View Full Analysis

What is iDNA Genomics Public ROE %?

iDNA Genomics Public CYS:IDNA 23 ROE % is 0.00% as of . 20. GuruFocus rates CYS:IDNA with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. iDNA Genomics Public's annualized net income for the quarter that ended in . 20 was € Mil. iDNA Genomics Public's average Total Stockholders Equity over the quarter that ended in . 20 was € Mil. Therefore, iDNA Genomics Public's annualized ROE % for the quarter that ended in . 20 was %.

The historical rank and industry rank for iDNA Genomics Public's ROE % or its related term are showing as below:

CYS:IDNA's ROE % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -1.31
* Ranked among companies with meaningful ROE % only.

iDNA Genomics Public  (CYS:IDNA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=( / )*( / )*( / )
=Net Margin %*Asset Turnover*Equity Multiplier
= %**
=ROA %*Equity Multiplier
= %*
= %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= ( / ) * ( / ) * ( / ) * ( / ) * ( / )
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= * * % * *
= %

Note: The net income data used here is one times the annual (. 20) net income data. The Revenue data used here is one times the annual (. 20) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

iDNA Genomics Public ROE % Related Terms

iDNA Genomics Public ROE % Historical Data

* Premium members only.

The historical data trend for iDNA Genomics Public's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iDNA Genomics Public ROE % Chart

iDNA Genomics Public Annual Data
Trend
ROE %

iDNA Genomics Public Semi-Annual Data
ROE %

CYS:IDNA vs : ROE % Comparison

For the Diagnostics & Research subindustry, iDNA Genomics Public's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iDNA Genomics Public ROE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iDNA Genomics Public's ROE % distribution charts can be found below:

* The bar in red indicates where iDNA Genomics Public's ROE % falls into.


CYS:IDNA
23GF Score
iDNA Genomics Public Ltd CYS:IDNA
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iDNA Genomics Public ROE % Calculation

iDNA Genomics Public's annualized ROE % for the fiscal year that ended in . 20 is calculated as

ROE %=Net Income (A: . 20 )/( (Total Stockholders Equity (A: . 20 )+Total Stockholders Equity (A: . 20 ))/ count )
=/( (+)/ )
=/
= %

iDNA Genomics Public's annualized ROE % for the quarter that ended in . 20 is calculated as

ROE %=Net Income (Q: . 20 )/( (Total Stockholders Equity (Q: . 20 )+Total Stockholders Equity (Q: . 20 ))/ count )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
iDNA Genomics Public (CYS:IDNA) has a ROE % of 0.00% as of . 20. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on iDNA Genomics Public and its competitors.
Is iDNA Genomics Public's ROE % too high?
iDNA Genomics Public's current ROE % is 0.00%. Overall, iDNA Genomics Public has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does iDNA Genomics Public's ROE % compare to ?
iDNA Genomics Public's ROE % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on iDNA Genomics Public and its competitors. iDNA Genomics Public's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iDNA Genomics Public stock overvalued right now?
iDNA Genomics Public (CYS:IDNA) has a current ROE % of 0.00%. The current ROE % is 0.00%. iDNA Genomics Public's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For iDNA Genomics Public (CYS:IDNA), the current ROE % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

iDNA Genomics Public Business Description

Comparable Companies
Address 7 Hatzidaki Street, Trypiotis, Nicosia, CYP, 1066
iDNA Genomics Public Ltd operates in the field of genomics and biotechnology and specializes in personalized health care. Its purpose is to develop and provide genetic tests in the field of genomics, through professionals (Medical Genomics) and directly to the consumer (Direct-to-Consumer Genomics).
23GF Score

Get the complete analysis for CYS:IDNA

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.80
Price